Emilsson Össur Ingi, Aspelund Thor, Janson Christer, Benediktsdottir Bryndis, Juliusson Sigurdur, Maislin Greg, Pack Allan I, Keenan Brendan T, Gislason Thorarinn
Department of Sleep, Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland.
Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
ERJ Open Res. 2023 Sep 10;9(5). doi: 10.1183/23120541.00387-2023. eCollection 2023 Sep.
To study the effect of positive airway pressure (PAP) treatment on nocturnal gastro-oesophageal reflux (nGOR) and respiratory symptoms among clinical obstructive sleep apnoea (OSA) patients.
822 patients newly diagnosed with OSA referred for PAP treatment were recruited. 732 patients had a 2-year follow-up visit with continuous PAP compliance data (366 full PAP users, 366 partial/non-PAP users). They answered questionnaires, including reporting of nGOR, sleep and respiratory symptoms and general health. Patients with nGOR symptoms once a week or more were defined as "with nGOR". Those without nGOR symptoms and nGOR medication were defined as "no nGOR". Others were defined as "possible nGOR".
At 2-year follow-up, PAP treatment among full users resulted in decreased nGOR (adjusted OR 0.58, 95% CI 0.40-0.86) and wheezing (adjusted OR 0.56, 95% CI 0.35-0.88) compared with partial/non-PAP users. Decreased nGOR, among both full and partial/non-users of PAP treatment, was associated with a decrease in productive morning cough (adjusted OR 4.70, 95% CI 2.22-9.99) and a decrease in chronic bronchitis (adjusted OR 3.86, 95% CI 1.74-8.58), but not decreased wheezing (adjusted OR 0.90, 95% CI 0.39-2.08). A mediation analysis found that PAP treatment directly led to a decrease in wheezing, not mediated through nGOR. Conversely, PAP treatment decreased productive cough mediated through a decrease in nGOR.
In an unselected group of OSA patients, PAP treatment for 2 years was associated with a decrease in nGOR and respiratory symptoms. The PAP treatment itself was associated with less wheezing. A decrease in nGOR through PAP treatment was associated with a decrease in productive cough.
研究气道正压通气(PAP)治疗对临床阻塞性睡眠呼吸暂停(OSA)患者夜间胃食管反流(nGOR)及呼吸症状的影响。
招募822例新诊断为OSA并接受PAP治疗的患者。732例患者进行了为期2年的随访,有持续的PAP依从性数据(366例完全PAP使用者,366例部分/非PAP使用者)。他们回答了问卷,包括nGOR、睡眠和呼吸症状以及总体健康状况的报告。每周出现一次或更多次nGOR症状的患者被定义为“有nGOR”。没有nGOR症状且未使用nGOR药物的患者被定义为“无nGOR”。其他患者被定义为“可能有nGOR”。
在2年随访时,与部分/非PAP使用者相比,完全使用者接受PAP治疗后nGOR(校正比值比0.58,95%可信区间0.40 - 0.86)和喘息(校正比值比0.56,95%可信区间0.35 - 0.88)有所减少。在PAP治疗的完全使用者和部分/非使用者中,nGOR的减少与晨起咳痰减少(校正比值比4.70,95%可信区间2.22 - 9.99)和慢性支气管炎减少(校正比值比3.86,95%可信区间1.74 - 8.58)相关,但与喘息减少无关(校正比值比0.90,95%可信区间0.39 - 2.08)。中介分析发现,PAP治疗直接导致喘息减少,并非通过nGOR介导。相反,PAP治疗通过减少nGOR介导晨起咳痰减少。
在未经选择的OSA患者组中,PAP治疗2年与nGOR和呼吸症状减少相关。PAP治疗本身与喘息减少相关。通过PAP治疗减少nGOR与晨起咳痰减少相关。